The Director, Distribution and GPO’s is responsible for developing and executing strategic trade plans for assigned accounts to support the successful launch of our lead oncology pipeline agent, Fotivda (tivozanib). Reporting to the Sr. Director of Trade & Distribution, this role will serve as the primary contact between Aveo and designated trade and distribution partners. The Director, Distribution and GPO’s, will lead all account initiatives and is responsible for achieving expected business objectives across the oncology portfolio of Aveo products. This role will collaborate with multiple stakeholders including sales, marketing, market access, medical affairs, HEOR, compliance/legal and finance to ensure successful commercialization of products within the oncology pipeline.
- Develop, define, and implement account strategy and objectives for the successful launch of the lead oncology pipeline agent, Fotivda (tivozanib).
- Ensure strong business relationships with assigned accounts
- Execute action plans to compliantly maximize market access for Aveo products
- Collaborate with sales, marketing, finance, legal/compliance, medical affairs, and market access to optimize strategic opportunities and initiatives
- Contribute effectively to pricing and contracting strategy development
- Effectively communicate account positioning with internal stakeholders regularly
- Continually assess the competitive landscape and adjust strategies and tactics accordingly
- Manage budgeted items and responsibilities for understanding of overall gross to net impact
- Monitor trends and potential coverage and reimbursement issues, existing and emerging government and payer policies, competitive pricing and contracting strategies, and potential barriers to provider and patient access.
- Minimum of a bachelor’s degree; advanced degree preferred
- 10+ years of progressive experience within sales, marketing, or managed markets roles in account management, formulary access, reimbursement, distribution, program development, contract negotiations and policy development
- At least 5 years of successful oncology account or sales management experience
- Previous new product launch experience in Oncology, preferably with start-up company
- Strong knowledge of distributor channel and GPO services
- Understand the business of oncology, distribution, discounting, contracting and reimbursement
- Experience and understanding of oral oncology product access channels
- Strong understanding of relevant health care laws, including anti-kickback statute and false claims act, to ensure compliant contracting
- Experience in contract strategy development
- Ability to negotiate effective contract decisions with assigned accounts
- Self-motivated, assertive, and self-confident with the ability to act with urgency and passion
- Proven ability to work with high level of integrity, accuracy, and attention to detail
- Strong organizational skills to maintain a high level of productivity, innovation, and prioritizing to complete assignments on time and within budget
- Ability to make thoughtful, timely and meaningful decisions to take corresponding actions
- Resourceful, creative, enthusiastic, and results oriented
- Flexible, adaptable, diplomatic, and able to effectively deal with ambiguity
- Entrepreneurial, enjoys working in a fast paced, small company environment
- Effective budget development and management skills; ability to collaborate cross functionally
- Strong interpersonal and teambuilding skills
- Willingness to travel and attend industry meetings as needed
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.